AOD
Fragment of human growth hormone (amino acids 176-191) studied for obesity in early-phase human trials; weight-loss efficacy was not established in published literature. Sponsor and preclinical data describe it as lacking the growth-promoting (IGF-1-raising) effects of HGH; no published human study found confirms this.
Regulatory status (as of Sept 2026)
Not FDA-approved. Listed as a prohibited substance in WADA doping-control screening (PMID 26578461, 25208511).
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
AOD-9604 is a compound whose development or US marketing has been discontinued. Fragment of human growth hormone (amino acids 176-191) studied for obesity in early-phase human trials; weight-loss efficacy was not established in published literature.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Discontinued |
| Dosing | Published research: No published human dosing detailsRabbit OA model: 0.25 mg intra-articular weekly (Kwon 2015). No PubMed-indexed human dose-ranging paper was found.Community-reportedCommunity-reported: 250–500 mcg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a piece of growth hormone that is said to help break down fat without growth hormone's other effects, but no published human study confirms this. Proposed mechanism, not confirmed in a published human study: a modified C-terminal fragment of human growth hormone (amino acids 177-191 with an added N-terminal tyrosine) that is reported to mimic the lipolytic (fat-breakdown) properties of growth hormone without its diabetogenic effects (as described by Cox 2015). Sponsor and preclinical data describe it as not raising IGF-1.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 250 to 500 mcg (subcutaneous injection). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| AOD-9604 | No published PK data found | Subcutaneous injection | Discontinued |
| 5-Amino-1MQ | Unknown | Oral | Preclinical (animal) |
| Adipotide (FTPP) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| Dulaglutide | ~5 days | Subcutaneous injection | FDA-approved |
| Exenatide | 2.4 hours (immediate-release) | Subcutaneous injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Metabolic category. View All Metabolic Peptides
Growth Hormone
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.